Figure 7. FAK is a potent therapeutic target in human DGC cell lines and patients.

A, Immunoblots from IGC cell lines: AGS, KE39,YCC-1 and SNU719, and DGC lines SNU668, NUGC4 and FU97 (n = 3 independent experiments). B, Quantification of pFAK levels from (A). C, Representative immunoblots of FU97,SNU668 and SNU719 cells treated for 24 h with DMSO or FAK inhibitor PF-573228 (5 μM) or defactinib (2.5 μM) (n = 3 independent experiments). D, In vitro proliferation of SNU668, NUGC4 and FU97 cells treated for indicated days with DMSO or PF-573228 (5 μM). Data are mean ± S.E.M. ****P<0.0001, two-way ANOVA. E, In vitro proliferation of SNU719 and AGS cells treated for the indicated days with DMSO or PF-573228 (5 μM). Data are mean ± S.E.M. ****P<0.0001, two-way ANOVA. F, Tumor volume of 1✕10⁶ SNU668 cells injected into flanks of NSG mice and treated with DMSO (n=4) or 5-FU (n=4, 50 mg/kg) or PF-573228 (n=6, 12.5 mg/kg) every other day, with representative images (bottom) of tumors from each group. *P<0.05, ****P<0.0001, two-way ANOVA (Treatments versus DMSO). Data are mean ± S.E.M. G, Representative images of H&E of tumors from panel (F). Scale bar = 100 μm. H, Tumor volume of 1✕10⁶ SNU719 cells injected into flanks of NSG mice and treated with DMSO (n=4) or 5-FU (n=5, 50 mg/kg) or PF-573228 (n=4, 12.5 mg/kg) every other day. ns, not significant, ****P<0.0001, two-way ANOVA (Treatment versus DMSO). Data are mean ± S.E.M. I, Representative images of pFAK staining for human diffuse gastric patients with tumor area (left), adjacent normal surface epithelial area (middle) and gland epithelial cells (right). Scale bar = 100 μm.